key: cord-0846554-efox6z5q
authors: Zaid, Younes; Doré, Étienne; Dubuc, Isabelle; Archambault, Anne-Sophie; Flamand, Olivier; Laviolette, Michel; Flamand, Nicolas; Boilard, Éric; Flamand, Louis
title: Chemokines and Eicosanoids Fuel the Hyperinflammation Within the Lungs of Patients with Severe COVID-19
date: 2021-06-07
journal: J Allergy Clin Immunol
DOI: 10.1016/j.jaci.2021.05.032
sha: c8151d13f101a4ef746c05963495130b972cf4c6
doc_id: 846554
cord_uid: efox6z5q

Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection can lead to a variety of clinical outcomes ranging from the absence of symptoms to severe acute respiratory disease and ultimately death. A feature of patients with severe Coronavirus disease 19 (COVID-19) is the abundance of inflammatory cytokines in the blood. Elevated levels of cytokine are predictive of infection severity and clinical outcome. In contrast, studies aimed at defining the driving forces behind the inflammation in lungs of severed COVID-19 subjects remain scarce. Objective To analyze and compare the plasma and bronchoalveolar lavages (BALs) of patients with severe COVID-19 (n=45) for the presence of cytokines and lipid mediators of inflammation (LMI). Methods Cytokines were measured using Luminex multiplex assay and LMI measured using LC-MS/MS. Results We reveal high concentrations of numerous cytokines/chemokines/LMI in BALs of patients with severe COVID-19. Among the 13 most abundant mediators in BALs, 11 were chemokines with CXCL1 and CXCL8 being 200 times more abundant than IL-6 and TNF-α. Eicosanoids were also elevated in lungs of severe COVID-19 subjects. Consistent with the presence chemotactic molecules, BALs were enriched for neutrophils, lymphocytes and eosinophils. Inflammatory cytokines/LMI in plasma showed limited correlations with those present in BALs, arguing that circulating inflammatory molecules may not be a reliable proxy of the inflammation occurring in the lungs of severe COVID-19 patients. Conclusions Our findings indicate that lungs hyperinflammation of severe COVID-19 patients is fueled by excessive production of chemokines and eicosanoids. Therapeutic strategies to dampen inflammation in COVID-19 patients should be tailored accordingly.

Coronavirus disease-19 is caused by the severe acute respiratory syndrome coronavirus 2 70 . (1) The disease spectrum associated with SARS-CoV-2 infection varies extensively 71 from asymptomatic, to severely ill with an estimated overall death rate of 2%. Soon after the initial characterization of SARS-CoV-2, it became clear that subjects with severe forms 83 of the disease showed enhanced levels of circulating inflammatory cytokines. Ever since, the 84 expression "cytokine storm" is used to describe the overwhelming and dysregulated immune response 85 triggered by the virus. The majority of studies have used blood/plasma/serum as biological matrices to 86 monitor the inflammatory response during COVID-19. In such studies, increased circulating levels of 87 interleukin 6 (IL-6), TNF-, IL-2R, IL-8, MCP-1, MIP-1 were measured relative to healthy subjects 88 or those with mild COVID-19.(2, 5, 6) Although statistically significant cytokine levels were 89 measured, in most cases the cytokine concentrations in severe COVID-19 patients, such as IL-6, are 90 10-to 200-fold lower than IL-6 levels typically observed in patients with ARDS-related 91 inflammation.(7-9) One question arising from these observations is whether blood, plasma or serum 92 represent reliable biological matrices to evaluate the extent and the nature of lung inflammation in 93 J o u r n a l P r e -p r o o f Clinical data and blood work. All laboratory blood work was performed in the COVID-19 laboratory 145 dedicated to the pandemic only at Cheikh Zaïd Hospital. Patients' demographic data, clinical reports, 2 146 laboratory blood work results, and treatment protocols were collected, analyzed and compared for 147 clinical outcomes. 148 Bronchoalveolar lavages. BAL fluids from healthy volunteers (n=25) were obtained as follows: One 149 50 ml bolus of sterile 0.9% saline was injected in a sub-segmental bronchus of the right middle lobe. 150

The recovered fluid was centrifuged (350 × g, 10 minutes) to pellet cells and the supernatants were 151 immediately frozen (-80˚ Celsius) until further processing. A 5 ml aliquot of the samples was thawed 152 then reduced to ~500 μl using a stream of nitrogen. BAL fluids from severe COVID-19 patients (n=45) 153 were obtained less than 2 hrs following intubation and as follows: a total of 100 ml of sterile 0.9% 154 saline (2 boli of 50 ml) was injected in a sub-segmental bronchus of the right middle lobe. The obtained 155 lavages were pooled and centrifuged (320 × g, 15 minutes) to pellet cells. Supernatants were next 156 concentrated as for the BALs of healthy donors using a stream of nitrogen and immediately frozen (-157 80˚ Celsius) until further processing. All of the evaporated samples were processed for LC-MS/MS 158 analysis as described below. 159 Plasma samples. Venous blood was drawn from healthy subjects (n=10; different from those who 160 provided BALs) and COVID-19 patients (n=45, same patients used for BAL) in accordance with 161 guidelines of the Ethics Committee of Cheikh Zaïd Hospital of Rabat. Blood samples were 162 anticoagulated in one-sixth volume of acid citrate dextrose (2.5 g of sodium citrate, 2 g of glucose, and 163 1.5 g of citric acid in 100 ml deionized water). Platelet-rich plasma was obtained by centrifugation of 164 anticoagulated blood at 200 x g for 15 minutes. Platelets were then removed from plasma by 165 centrifugation (1000 x g for 10min). Platelet-free plasma were aliquoted and stored frozen until assayed 166 for cytokine content. 167 J o u r n a l P r e -p r o o f Cytokine assay. Cytokine levels in plasma were assessed by Eve Technologies Corp. (Calgary, AB, 168 Canada) using the Human Cytokine Array / Chemokine Array 71-Plex (HD71). BAL samples were 169 diluted 1:5 with saline before analysis. Cytokine levels are reported as pg/mL of plasma and pg/mL of 170 recuperated BAL fluids. 

Statistical analyses were done using the GraphPad Prism 9 software. Data were tested for normal 177 distribution by Shapiro-Wilk test. Data that fit the assumption of normal distribution were compared 178 using parametric analysis indicated in the respective figure legends: Student´s unpaired or paired t-test 179 were used for comparing data from two groups. Data that did not fit the assumption of normal 180 distribution were compared using non-parametric analysis indicated in the respective figure legends. 181

Non-parametric A correlation matrix was calculated comparing BAL and plasma analytes as well as 182 biochemical variables in a pairwise fashion using the corr.test function from pshych CRAN package: 183 the corrplot package was subsequently used to graphically display the correlation matrix. Spearman 184 correlation coefficients were indicated by a heat scale whereby blue color shows positive linear 185 correlation and red color shows negative linear correlation. p values < 0.05 were considered 186 significant. 187

The plasma of 45 severe COVID-19 patients were analyzed for their content in 71 190 cytokines/chemokines. As reported by others,(2, 5, 6) many of the analytes measured were present at 191 significantly higher concentrations in the blood of COVID-19 patients relative to healthy controls 192 J o u r n a l P r e -p r o o f ( Figure 1 ). Cytokines such as IL-1, IL-, TNF, and IFN were all elevated ( Figure 1A ) while no 193 significant differences in IL-6 levels were noted. Chemokines of the CC family, notably CCL2, CCL3, 194 CCL4, CCL5, and CCL11 were present at significantly higher concentrations in the blood of 19 patients ( Figure 1B) . Chemokines of the CXC family were also significantly upregulated, notably 196 CXCL1 and CXCL8 ( Figure 1C 2B) and CXC chemokines ( Figure 2C ) were detected. The most abundant analytes measured were 205 CXCL1, CXCL8, CCL2 and CCL15. For comparison purposes, BAL fluids from healthy subjects were 206 analyzed for the same analytes. Acknowledging potential biases due to differences in age and 207 medication taken, all analytes measured with the exception of IL-28A were detected at significantly 208 higher concentrations in BALs of severe COVID-19 subjects relative to healthy subjects. Correlations 209 between analytes were subsequently analyzed. An example of positive correlation between CXCL1 and 210 CXCL8 (r=0.097, p<0.0001) is presented in Figure 2D . Correlation matrix of BAL analytes is 211 presented under Figure 2E . As shown, very significant positive correlations were observed between 212 most BAL cytokines analyzed. 213

Lipid mediators (LM) represent another important class of molecules that play very important roles in 215 inflammation and whose contributions to COVID-19 disease remain understudied. LM of the 216 eicosanoid class originate from the processing of arachidonic acid, generated by the cleavage of 217 membrane phospholipids by phospholipase A 2 ( Figure 2F ). Arachidonic acid can be processed by 218 cyclooxygenases and lipoxygenases to produce prostaglandins/thromboxanes and leukotrienes. BAL 219 fluids of healthy and severe COVID-19 subjects were analyzed for the presence of selected 220 eicosanoids. Relative to healthy controls, PGE 2 , TXB 2 , 12-HHTrE and LTB 4 were detected at 221 significantly higher concentrations in BAL of COVID-19 subjects. Such LM showed significant 222 positive correlations with most BAL cytokines analyzed ( Figure 2G Increased levels of LTB 4 , LTB 4 metabolites and other eicosanoids were measured in BAL fluids of 336 COVID-19 subjects, suggesting that LTB4 likely contributes to the observed neutrophil pulmonary 337 influx recorded. These results are concordant with the study of Schwarz et al(19) and a yet to be 338 published study where the lipidome present in BALs of severe COVID-19 patients was analyzed. (44) 339 Lymphocytes were also detected at high number in the BAL fluid of severe COVID-19 patients. 340

Although the characterization of lymphocyte sub-populations was not performed, many of them, such 341 as NK, NKT, TH1, Treg express one or several chemokine receptors such as CCR4, CCR5 and CXCR3 342 arguing that chemokines such as CCL2, CCL3, CCL4, CCL5, CXCL9 and CXCL10, which are all 343 elevated in the lungs of COVID-19 patients, are likely contributing to lymphocyte recruitment. leading to misleading observations. In our study, we depleted platelets by centrifugation, which 361 permitted the evaluation of circulating inflammatory mediators released in the extracellular milieu. In a 362 recent report, we documented that platelets were hyperactivated during COVID-19, that viral RNA can 363 be found associated with platelets and that increased platelet contents, indicative of platelet activation 364 and degranulation, is detected in plasma of patients. (16) Furthermore, our work also indicates that 365 platelets from COVID-19 patients are hyperresponsive to thrombin relative to platelets of subjects with 366 ARDS unrelated to In the current study, we provide evidence that plasma and BAL 367 fluids of severe COVID-19 patients contain significantly elevated levels of CXCL1, CXCL8, CXCL12, 368 CCL2, CCL3, CCL5, EGF, VEGF and PDGF-AB/BB, all of which can be found in platelet granules, 369

arguing that platelets are important contributors of the hyperinflammation observed in ARDS patients. 370

In fact, many of these cytokines/chemokines/growth factors work in synergy, fueling the inflammatory 371 response through autocrine and paracrine pathways. 372 373 Overall, our results indicate that BALs of severe COVID-19 subjects contained very high 374 concentrations of the following cytokines: CXCL1 = CXCL8 > CCL2 = CXCL9 > CXCL15. 375

Cytokines such as IL-1, TNF- and IL-6 were present at much lower concentrations. Several ongoing 376 trials are currently exploring the possibility of using biologics (anti-IL1, anti-IL-6, anti-TNF-) 377

initially developed for the treatment of chronic inflammatory disease such as rheumatoid arthritis. Time 378 will tell whether such specific treatments will provide clinical benefits to severe COVID-19 patients. 379

Our results would argue that drugs with broader anti-inflammatory activities, such as the blockade of 380 cytokine signaling (e.g., JAK inhibition), would provide the greater benefits. In support, relative to 381 remdesivir-treated COVID-19 patients, those receiving remdesivir plus Baricitinib, a Jak inhibitor with 382 activity against JAK1 and JAK2, had reduced recovery times and improved clinical status, notably 383 among those receiving high-flow oxygen or noninvasive ventilation.(57) Recent data from the 384 RECOVERY trial also indicate that administration of dexamethasone, a glucocorticoid that inhibits 385 neutrophil migration (among other effects), resulted in a reduced 28-day mortality of COVID-19 386 patients.(58) With regard to platelets, there are currently insufficient data to recommend either for or 387 against using therapeutic doses of antithrombotic or thrombolytic agents for COVID-19 in patients who 388 are hospitalized. 389 J o u r n a l P r e -p r o o f Our study has the following limitations. First, the age of severe COVID-19 patients is greater than 391 those of our healthy controls, both for plasma and BALs. This could have an impact on the level of 392 certain mediators measured. Second, the procedure to obtain BAL fluids is slightly different between 393 healthy subjects and severe COVID-19 patients. The volume of saline injected to healthy subjects was 394 50 ml while that of severe COVID-19 patients was 100 ml. Analysis of cytokines/chemokines/growth factors in plasma of severe COVID-19 patients (n=45) and 581 healthy subjects (n=10). A) Plasmatic concentrations of various cytokines, B) CC chemokines and C) 582 CXC chemokines in controls and severe COVID-19 subjects. D) Example of positive correlation 583 between IL-1 and CXCL8. E) Example of negative correlation between CXCL5 and CCl3. F) 584

Summary of Spearman correlations between plasma analytes of severe COVID-19 subjects. Results are 585

presented as scattered plots with median concentrations shown by horizontal bars. HS= Healthy 586 subjects; COVID-19=severe COVID-19 patients. **p<0.005, ****p<0.0001 as determined using the 

Platelets Can Associate with 465 SARS-Cov-2 RNA and Are Hyperactivated in COVID-19

CoV-2 Immunostaining in the Lung of a Patient With COVID-19

The differential immune responses to 470 COVID-19 in peripheral and lung revealed by single-cell RNA sequencing

Cutting Edge: Severe 472 SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in 473 Dysregulation of Eicosanoid Immune Mediators

Endocannabinoid hydrolysis inhibition unmasks that unsaturated fatty acids induce a robust 478 biosynthesis of 2-arachidonoyl-glycerol and its congeners in human myeloid leukocytes

Serum Cytokine and Chemokine Profile in 481 Relation to the Severity of Coronavirus Disease 2019 in China

Constitutive and stimulated MCP-1, GRO alpha, beta, 483 and gamma expression in human airway epithelium and bronchoalveolar macrophages

Transcriptional 486 activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar epithelial cells: 487 nuclear translocation of the RelA transcription factor as a mechanism producing airway mucosal 488 inflammation

Neutrophil chemoattractant receptors in health and 490 disease: double-edged swords

Evolution of 492 bronchoalveolar cell populations in the adult respiratory distress syndrome

Broncho-497 alveolar inflammation in COVID-19 patients: a correlation with clinical outcome

Delayed induction of 503 proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East 504 respiratory syndrome coronavirus: implications for pathogenesis and treatment

Innate 507 immune dysfunction is associated with enhanced disease severity in infants with severe respiratory 508 syncytial virus bronchiolitis

Expression profile of 510 immune response genes in patients with Severe Acute Respiratory Syndrome

New fronts emerge in the influenza cytokine storm. Semin 515 Immunopathol

MERS-517 CoV infection is associated with downregulation of genes encoding Th1 and Th2 518 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory 519 tract

Comparative and kinetic 521 analysis of viral shedding and immunological responses in MERS patients representing a broad 522 spectrum of disease severity

Active replication of Middle East 524 respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in 525 human macrophages: implications for pathogenesis

Cytokine levels in bronchoalveolar lavage and serum in 3 patients with 2009 527 Influenza A(H1N1)v severe pneumonia

Leukotriene B, a potent 531 chemokinetic and aggregating substance released from polymorphonuclear leukocytes

Leukotriene B4: 534 a highly potent and stereospecific factor stimulating migration of polymorphonuclear leukocytes

Lipid storm 541 within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-542 derived inflammatory metabolites

Impaired type I 544 interferon activity and inflammatory responses in severe COVID-19 patients

Imbalanced 547 Host Response to SARS-CoV-2 Drives Development of COVID-19

Activation and evasion of type I 549 interferon responses by SARS-CoV-2

Evasion of Type I Interferon by 551 SARS-CoV-2

Extrapulmonary 553 manifestations of COVID-19

Nouvelle cuisine: platelets served with 555 inflammation

Platelet 559 Function in Viral Immunity and SARS-CoV-2 Infection

Platelets, inflammation and anti-inflammatory 561 effects of antiplatelet drugs in ACS and CAD. Thrombosis and haemostasis

The inflammatory 563 chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-564 dependent phosphatidylinositide 3-kinase/Akt signaling

Platelet chemokines in vascular disease

Platelet 568 reactivity to thrombin differs between COVID-19 patients and those with ARDS unrelated to COVID-569 19

Dexamethasone in 573 Hospitalized Patients with Covid-19 -Preliminary Report

0001 as determined using the Mann-Whitney non-parametric test

Spearman correlation coefficients were calculated to study association between cytokines

Spearman correlation between cytokines/chemokines/LM and biochemical, hematological and Legend for Figure E1

Spearman correlation between cytokines/chemokines in plasma and BAL fluids of subjects with severe 2 COVID-19

Proposed lung pathophysiology associated with SARS-CoV-2 infection. J o u r n a l P r e -p r o o f